ÖZCAN, M. Et Al. 2020. Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study. 62th ASH Meeting , (Turkey), 19-20.

ÖZCAN, M., Ramchandren, R., Zinzani, P. L., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., ... Johnson, N. A.(2020). Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study . 62th ASH Meeting (pp.19-20). , Turkey

ÖZCAN, MUHİT Et Al. "Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study," 62th ASH Meeting, Turkey, 2020

ÖZCAN, MUHİT Et Al. "Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study." 62th ASH Meeting , Turkey, pp.19-20, 2020

ÖZCAN, M. Et Al. (2020) . "Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study." 62th ASH Meeting , Turkey, pp.19-20.

@conferencepaper{conferencepaper, author={MUHİT ÖZCAN Et Al. }, title={Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study}, congress name={62th ASH Meeting}, city={}, country={Turkey}, year={2020}, pages={19-20} }